COVID-19 vaccines: are we good to go?

Abstract

The COVID-19 pandemic has accelerated unprecedented research of experimental treatments as well as using established drugs in new ways. At the end of November 2020, we reflected on the various therapies for COVID-19 that had received regulatory full or emergency use authorisation including the convalescent plasma-derived IgG1 antibodies, bamlanivimab, and the casirivimab-imdevimab cocktail, that provide passive immunity in patients with mild to moderate disease who are at risk for severe illness, the intravenous antiviral, remdesivir, for patients with severe disease requiring hospitalisation, as well as the WHO-endorsed systemic inexpensive glucocorticoids such as dexamethasone, hydrocortisone, methylprednisolone or prednisone for critically ill patients requiring oxygen.1